CEL-SCI logo

CVM - CEL-SCI News Story

$12.02 0.1  0.8%

Last Trade - 9:10pm

Sector
Healthcare
Size
Small Cap
Market Cap £343.2m
Enterprise Value £337.9m
Revenue £451k
Position in Universe 3182nd / 6444

BRIEF-Cel-Sci Reports Recent Data Review By The Independent Data Monitoring Committee For Its Pivotal Phase 3 Head And Neck Cancer Study

Thu 23rd April, 2020 2:17pm
April 23 (Reuters) - CEL-SCI Corp  CVM.A :
    * CEL-SCI REPORTS RECENT DATA REVIEW BY THE INDEPENDENT DATA
MONITORING COMMITTEE FOR ITS PIVOTAL PHASE 3 HEAD AND NECK
CANCER STUDY
    * CEL-SCI CORP - IDMC "AGREES WITH CONTINUING TRIAL WITHOUT
CHANGE" FOR CO'S PIVOTAL PHASE 3 HEAD AND NECK CANCER STUDY

Source text for Eikon:  ID:nBw7c5kGMa 
Further company coverage:  CVM.A 

 ((Reuters.Briefs@thomsonreuters.com;))
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.